Interaction Checker

Lomitapid: interakcje

Lomitapid (Juxtapid): 133 udokumentowane interakcje w indeksowanych przez nas etykietach FDA i kartach informacyjnych. Poważne: 41, umiarkowane: 83, niewielkie: 9, pary, dla których etykieta nie zgłasza istotnej interakcji: 0. Każda pozycja poniżej cytuje zdanie, na którym się opiera. Ta strona leku to punkt wyjścia, a nie rozstrzygnięcie dla indywidualnej sytuacji.

Interakcje z etykiety

Poważne interakcje (41)

  • Amiodaronlek przeciwarytmicznyPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Aprepitantinhibitor CYP3A4Poważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Atazanawirlek przeciwretrowirusowyPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Cenobamatlek przeciwdrgawkowyPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Cyklosporynalek immunosupresyjnyPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Cymetydynaantagonista receptora H2Poważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • CyprofloksacynafluorochinolonPoważna

    Concomitant use of moderate CYP3A4 inhibitors (such as amprenavir, aprepitant, atazanavir, ciprofloxacin, crizotinib, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, imatinib, verapamil) has not been studied, but concomitant use with lomitapide is contraindicated since lomitapide exposure will likely increase significantly in the presence… (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Darunawirlek przeciwretrowirusowyPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Darunawir + kobicystatlek przeciwretrowirusowyPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Diltiazembloker kanału wapniowegoPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Dronedaronlek przeciwarytmicznyPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Efawirenzlek przeciwretrowirusowyPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Efawirenz + lamiwudyna + tenofowirlek przeciwretrowirusowyPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Elwitegrawir + kobicystat + emtrycytabina + tenofowirlek przeciwretrowirusowyPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Erytromycynaantybiotyk makrolidowyPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Ewerolimuslek immunosupresyjnyPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Flukonazolazolowy lek przeciwgrzybiczyPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Fosamprenawirlek przeciwretrowirusowyPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Fosaprepitantinhibitor CYP3A4Poważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • GrejpfrutŻywność i napojePoważna

    Patients must avoid grapefruit juice ( 4 , 5.6 , 7.1 ). (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Imatynibinhibitor CYP3A4Poważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Itrakonazolazolowy lek przeciwgrzybiczyPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Iwakaftorinhibitor CYP3A4Poważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • IzoniazydantybiotykPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Ketokonazolazolowy lek przeciwgrzybiczyPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Klarytromycynaantybiotyk makrolidowyPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Lenakapawirlek przeciwretrowirusowyPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Lopinawir + rytonawirlek przeciwretrowirusowyPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Mifeprystoninhibitor CYP3A4Poważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Mirabegronagonista receptorów beta-adrenergicznychPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Nefazodonlek przeciwdepresyjnyPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Nirmatrelwir + rytonawirlek przeciwwirusowyPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Palbocyklibinhibitor CYP3A4Poważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Perampanellek przeciwdrgawkowyPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Pozakonazolazolowy lek przeciwgrzybiczyPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Ranolazynalek wydłużający odstęp QTPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Rytonawirlek przeciwretrowirusowyPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Suworeksantlek uspokajająco-nasennyPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Tikagrelorlek przeciwpłytkowyPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Werapamilbloker kanału wapniowegoPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

  • Worykonazolazolowy lek przeciwgrzybiczyPoważna

    Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ]. (etykieta leku Lomitapid, Przeciwwskazania)

Umiarkowane interakcje (83)

  • Aliskirenlek przeciwnadciśnieniowyUmiarkowana

    Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates. (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • AlkoholAlkoholUmiarkowana

    Alcohol may increase levels of hepatic fat and induce or exacerbate liver injury. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • AlprazolambenzodiazepinaUmiarkowana

    Weak CYP3A4 Inhibitors Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology… (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • AmbrisentanUmiarkowana

    Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates. (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Amlodypinadihydropirydynowy bloker kanału wapniowegoUmiarkowana

    Weak CYP3A4 Inhibitors Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology… (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Amlodypina + atorwastatynadihydropirydynowy bloker kanału wapniowegoUmiarkowana

    Weak CYP3A4 Inhibitors Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology… (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Amlodypina + benazepryldihydropirydynowy bloker kanału wapniowegoUmiarkowana

    Weak CYP3A4 Inhibitors Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology… (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Amlodypina + olmesartandihydropirydynowy bloker kanału wapniowegoUmiarkowana

    Weak CYP3A4 Inhibitors Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology… (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Amlodypina + walsartandihydropirydynowy bloker kanału wapniowegoUmiarkowana

    Weak CYP3A4 Inhibitors Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology… (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • AtorwastatynastatynaUmiarkowana

    Weak CYP3A4 Inhibitors Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology… (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • BikalutamidandrogenUmiarkowana

    Weak CYP3A4 Inhibitors Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology… (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Butalbital + paracetamolbarbituranUmiarkowana

    Caution should be exercised when JUXTAPID is used with other medications known to have potential for hepatotoxicity, such as isotretinoin, amiodarone, acetaminophen (>4 g/day for ≥3 days/week), methotrexate, tetracyclines, and tamoxifen. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Butalbital + paracetamol + kofeinabarbituranUmiarkowana

    Caution should be exercised when JUXTAPID is used with other medications known to have potential for hepatotoxicity, such as isotretinoin, amiodarone, acetaminophen (>4 g/day for ≥3 days/week), methotrexate, tetracyclines, and tamoxifen. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Butalbital + paracetamol + kofeina + kodeinabarbituranUmiarkowana

    Caution should be exercised when JUXTAPID is used with other medications known to have potential for hepatotoxicity, such as isotretinoin, amiodarone, acetaminophen (>4 g/day for ≥3 days/week), methotrexate, tetracyclines, and tamoxifen. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Cylostazollek przeciwpłytkowyUmiarkowana

    Weak CYP3A4 Inhibitors Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology… (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Dabigatranlek przeciwzakrzepowyUmiarkowana

    Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates. (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Demeklocyklinaantybiotyk tetracyklinowyUmiarkowana

    Caution should be exercised when JUXTAPID is used with other medications known to have potential for hepatotoxicity, such as isotretinoin, amiodarone, acetaminophen (>4 g/day for ≥3 days/week), methotrexate, tetracyclines, and tamoxifen. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Dezogestrel + etynyloestradioldoustny środek antykoncepcyjnyUmiarkowana

    Careful titration may then be considered based on LDL-C response and safety/tolerability to a maximum recommended dosage of 30 mg daily except when coadministered with oral contraceptives, in which case the maximum recommended lomitapide dosage is 40 mg daily [see Dosage and Administration (2.3) and Drug Interactions (7.2) ]. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Digoksynaglikozyd naparstnicyUmiarkowana

    Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates. (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Dioctan etynodiolu + etynyloestradioldoustny środek antykoncepcyjnyUmiarkowana

    Careful titration may then be considered based on LDL-C response and safety/tolerability to a maximum recommended dosage of 30 mg daily except when coadministered with oral contraceptives, in which case the maximum recommended lomitapide dosage is 40 mg daily [see Dosage and Administration (2.3) and Drug Interactions (7.2) ]. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Doksycyklinaantybiotyk tetracyklinowyUmiarkowana

    Caution should be exercised when JUXTAPID is used with other medications known to have potential for hepatotoxicity, such as isotretinoin, amiodarone, acetaminophen (>4 g/day for ≥3 days/week), methotrexate, tetracyclines, and tamoxifen. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Drospirenon + etynyloestradioldoustny środek antykoncepcyjnyUmiarkowana

    Careful titration may then be considered based on LDL-C response and safety/tolerability to a maximum recommended dosage of 30 mg daily except when coadministered with oral contraceptives, in which case the maximum recommended lomitapide dosage is 40 mg daily [see Dosage and Administration (2.3) and Drug Interactions (7.2) ]. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • EstradiolestrogenUmiarkowana

    Careful titration may then be considered based on LDL-C response and safety/tolerability to a maximum recommended dosage of 30 mg daily except when coadministered with oral contraceptives, in which case the maximum recommended lomitapide dosage is 40 mg daily [see Dosage and Administration (2.3) and Drug Interactions (7.2) ]. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Estradiol + dienogestdoustny środek antykoncepcyjnyUmiarkowana

    Careful titration may then be considered based on LDL-C response and safety/tolerability to a maximum recommended dosage of 30 mg daily except when coadministered with oral contraceptives, in which case the maximum recommended lomitapide dosage is 40 mg daily [see Dosage and Administration (2.3) and Drug Interactions (7.2) ]. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Estradiol + noretysteronestrogenUmiarkowana

    Careful titration may then be considered based on LDL-C response and safety/tolerability to a maximum recommended dosage of 30 mg daily except when coadministered with oral contraceptives, in which case the maximum recommended lomitapide dosage is 40 mg daily [see Dosage and Administration (2.3) and Drug Interactions (7.2) ]. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Estrogeny estryfikowane + metylotestosteronestrogenUmiarkowana

    Careful titration may then be considered based on LDL-C response and safety/tolerability to a maximum recommended dosage of 30 mg daily except when coadministered with oral contraceptives, in which case the maximum recommended lomitapide dosage is 40 mg daily [see Dosage and Administration (2.3) and Drug Interactions (7.2) ]. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Estrogeny skoniugowaneestrogenUmiarkowana

    Careful titration may then be considered based on LDL-C response and safety/tolerability to a maximum recommended dosage of 30 mg daily except when coadministered with oral contraceptives, in which case the maximum recommended lomitapide dosage is 40 mg daily [see Dosage and Administration (2.3) and Drug Interactions (7.2) ]. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Estrogeny skoniugowane + bazedoksyfenestrogenUmiarkowana

    Careful titration may then be considered based on LDL-C response and safety/tolerability to a maximum recommended dosage of 30 mg daily except when coadministered with oral contraceptives, in which case the maximum recommended lomitapide dosage is 40 mg daily [see Dosage and Administration (2.3) and Drug Interactions (7.2) ]. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Etonogestrel + etynyloestradiolestrogenUmiarkowana

    Careful titration may then be considered based on LDL-C response and safety/tolerability to a maximum recommended dosage of 30 mg daily except when coadministered with oral contraceptives, in which case the maximum recommended lomitapide dosage is 40 mg daily [see Dosage and Administration (2.3) and Drug Interactions (7.2) ]. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Ezetymib + symwastatynastatynaUmiarkowana

    Risk of Myopathy with Concomitant Use of Simvastatin or Lovastatin The risk of myopathy, including rhabdomyolysis, with simvastatin and lovastatin monotherapy is dose related. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Feksofenadynalek przeciwhistaminowyUmiarkowana

    Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates. (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • FluoksetynaSSRIUmiarkowana

    Weak CYP3A4 Inhibitors Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology… (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • FluwoksaminaSSRIUmiarkowana

    Weak CYP3A4 Inhibitors Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology… (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • FulwestrantestrogenUmiarkowana

    Careful titration may then be considered based on LDL-C response and safety/tolerability to a maximum recommended dosage of 30 mg daily except when coadministered with oral contraceptives, in which case the maximum recommended lomitapide dosage is 40 mg daily [see Dosage and Administration (2.3) and Drug Interactions (7.2) ]. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Hydrokodon + paracetamolopioidUmiarkowana

    Caution should be exercised when JUXTAPID is used with other medications known to have potential for hepatotoxicity, such as isotretinoin, amiodarone, acetaminophen (>4 g/day for ≥3 days/week), methotrexate, tetracyclines, and tamoxifen. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • IzotretynoinaretinoidUmiarkowana

    Caution should be exercised when JUXTAPID is used with other medications known to have potential for hepatotoxicity, such as isotretinoin, amiodarone, acetaminophen (>4 g/day for ≥3 days/week), methotrexate, tetracyclines, and tamoxifen. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • KolchicynaUmiarkowana

    Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates. (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Kolesewelamsekwestrant kwasów żółciowychUmiarkowana

    Bile Acid Sequestrants: Separate JUXTAPID dosing by at least 4 hours ( 7.6 ). (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Kolestypolsekwestrant kwasów żółciowychUmiarkowana

    Bile Acid Sequestrants: Separate JUXTAPID dosing by at least 4 hours ( 7.6 ). (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Kolestyraminasekwestrant kwasów żółciowychUmiarkowana

    Bile Acid Sequestrants: Separate JUXTAPID dosing by at least 4 hours ( 7.6 ). (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Lapatynibinhibitor glikoproteiny PUmiarkowana

    …Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology (12.3) ] . (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • LewonorgestrelprogestagenUmiarkowana

    Careful titration may then be considered based on LDL-C response and safety/tolerability to a maximum recommended dosage of 30 mg daily except when coadministered with oral contraceptives, in which case the maximum recommended lomitapide dosage is 40 mg daily [see Dosage and Administration (2.3) and Drug Interactions (7.2) ]. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Lewonorgestrel + etynyloestradioldoustny środek antykoncepcyjnyUmiarkowana

    Careful titration may then be considered based on LDL-C response and safety/tolerability to a maximum recommended dosage of 30 mg daily except when coadministered with oral contraceptives, in which case the maximum recommended lomitapide dosage is 40 mg daily [see Dosage and Administration (2.3) and Drug Interactions (7.2) ]. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • LowastatynastatynaUmiarkowana

    Risk of Myopathy with Concomitant Use of Simvastatin or Lovastatin The risk of myopathy, including rhabdomyolysis, with simvastatin and lovastatin monotherapy is dose related. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Marawiroklek przeciwretrowirusowyUmiarkowana

    Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates. (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • MedroksyprogesteronprogestagenUmiarkowana

    Careful titration may then be considered based on LDL-C response and safety/tolerability to a maximum recommended dosage of 30 mg daily except when coadministered with oral contraceptives, in which case the maximum recommended lomitapide dosage is 40 mg daily [see Dosage and Administration (2.3) and Drug Interactions (7.2) ]. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • MegestrolprogestagenUmiarkowana

    Careful titration may then be considered based on LDL-C response and safety/tolerability to a maximum recommended dosage of 30 mg daily except when coadministered with oral contraceptives, in which case the maximum recommended lomitapide dosage is 40 mg daily [see Dosage and Administration (2.3) and Drug Interactions (7.2) ]. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Metotreksatlek immunosupresyjnyUmiarkowana

    Caution should be exercised when JUXTAPID is used with other medications known to have potential for hepatotoxicity, such as isotretinoin, amiodarone, acetaminophen (>4 g/day for ≥3 days/week), methotrexate, tetracyclines, and tamoxifen. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Miłorząb japoński (Ginkgo biloba)Zioła i suplementyUmiarkowana

    Weak CYP3A4 Inhibitors Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology… (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Minocyklinaantybiotyk tetracyklinowyUmiarkowana

    Caution should be exercised when JUXTAPID is used with other medications known to have potential for hepatotoxicity, such as isotretinoin, amiodarone, acetaminophen (>4 g/day for ≥3 days/week), methotrexate, tetracyclines, and tamoxifen. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Nilotyniblek wydłużający odstęp QTUmiarkowana

    …Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology (12.3) ] . (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Norelgestromin + etynyloestradiolestrogenUmiarkowana

    Careful titration may then be considered based on LDL-C response and safety/tolerability to a maximum recommended dosage of 30 mg daily except when coadministered with oral contraceptives, in which case the maximum recommended lomitapide dosage is 40 mg daily [see Dosage and Administration (2.3) and Drug Interactions (7.2) ]. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • NoretysteronprogestagenUmiarkowana

    Careful titration may then be considered based on LDL-C response and safety/tolerability to a maximum recommended dosage of 30 mg daily except when coadministered with oral contraceptives, in which case the maximum recommended lomitapide dosage is 40 mg daily [see Dosage and Administration (2.3) and Drug Interactions (7.2) ]. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Noretysteron + etynyloestradioldoustny środek antykoncepcyjnyUmiarkowana

    Careful titration may then be considered based on LDL-C response and safety/tolerability to a maximum recommended dosage of 30 mg daily except when coadministered with oral contraceptives, in which case the maximum recommended lomitapide dosage is 40 mg daily [see Dosage and Administration (2.3) and Drug Interactions (7.2) ]. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Norgestrel + etynyloestradioldoustny środek antykoncepcyjnyUmiarkowana

    Careful titration may then be considered based on LDL-C response and safety/tolerability to a maximum recommended dosage of 30 mg daily except when coadministered with oral contraceptives, in which case the maximum recommended lomitapide dosage is 40 mg daily [see Dosage and Administration (2.3) and Drug Interactions (7.2) ]. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Norgestymat + etynyloestradioldoustny środek antykoncepcyjnyUmiarkowana

    Careful titration may then be considered based on LDL-C response and safety/tolerability to a maximum recommended dosage of 30 mg daily except when coadministered with oral contraceptives, in which case the maximum recommended lomitapide dosage is 40 mg daily [see Dosage and Administration (2.3) and Drug Interactions (7.2) ]. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Oksykodon + paracetamolopioidUmiarkowana

    Caution should be exercised when JUXTAPID is used with other medications known to have potential for hepatotoxicity, such as isotretinoin, amiodarone, acetaminophen (>4 g/day for ≥3 days/week), methotrexate, tetracyclines, and tamoxifen. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Olanzapina + fluoksetynalek przeciwpsychotycznyUmiarkowana

    Weak CYP3A4 Inhibitors Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology… (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Olmesartan + amlodypina + hydrochlorotiazydantagonista receptora angiotensyny II (ARB)Umiarkowana

    Weak CYP3A4 Inhibitors Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology… (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • ParacetamolUmiarkowana

    Caution should be exercised when JUXTAPID is used with other medications known to have potential for hepatotoxicity, such as isotretinoin, amiodarone, acetaminophen (>4 g/day for ≥3 days/week), methotrexate, tetracyclines, and tamoxifen. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Paracetamol + ibuprofenNLPZUmiarkowana

    Caution should be exercised when JUXTAPID is used with other medications known to have potential for hepatotoxicity, such as isotretinoin, amiodarone, acetaminophen (>4 g/day for ≥3 days/week), methotrexate, tetracyclines, and tamoxifen. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Paracetamol + kodeinaopioidUmiarkowana

    Caution should be exercised when JUXTAPID is used with other medications known to have potential for hepatotoxicity, such as isotretinoin, amiodarone, acetaminophen (>4 g/day for ≥3 days/week), methotrexate, tetracyclines, and tamoxifen. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • PazopanibUmiarkowana

    …Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology (12.3) ] . (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Probenecyd + kolchicynaUmiarkowana

    Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates. (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • ProgesteronprogestagenUmiarkowana

    Careful titration may then be considered based on LDL-C response and safety/tolerability to a maximum recommended dosage of 30 mg daily except when coadministered with oral contraceptives, in which case the maximum recommended lomitapide dosage is 40 mg daily [see Dosage and Administration (2.3) and Drug Interactions (7.2) ]. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Ranitydynaantagonista receptora H2Umiarkowana

    …Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology (12.3) ] . (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Saksagliptynainhibitor DPP-4Umiarkowana

    Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates. (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Saksagliptyna + metforminainhibitor DPP-4Umiarkowana

    Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates. (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • SymwastatynastatynaUmiarkowana

    Risk of Myopathy with Concomitant Use of Simvastatin or Lovastatin The risk of myopathy, including rhabdomyolysis, with simvastatin and lovastatin monotherapy is dose related. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Syrolimuslek immunosupresyjnyUmiarkowana

    Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates. (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Sytagliptynainhibitor DPP-4Umiarkowana

    Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates. (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Sytagliptyna + metforminainhibitor DPP-4Umiarkowana

    Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates. (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Tamoksyfenselektywny modulator receptora estrogenowegoUmiarkowana

    Caution should be exercised when JUXTAPID is used with other medications known to have potential for hepatotoxicity, such as isotretinoin, amiodarone, acetaminophen (>4 g/day for ≥3 days/week), methotrexate, tetracyclines, and tamoxifen. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Telmisartan + amlodypinaantagonista receptora angiotensyny II (ARB)Umiarkowana

    Weak CYP3A4 Inhibitors Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology… (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Tetracyklinaantybiotyk tetracyklinowyUmiarkowana

    Caution should be exercised when JUXTAPID is used with other medications known to have potential for hepatotoxicity, such as isotretinoin, amiodarone, acetaminophen (>4 g/day for ≥3 days/week), methotrexate, tetracyclines, and tamoxifen. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • TolwaptanUmiarkowana

    Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates. (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • TopotekanUmiarkowana

    Coadministration of lomitapide with P-gp substrates (such as aliskiren, ambrisentan, colchicine, dabigatran etexilate, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) may increase the absorption of P-gp substrates. (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Tramadol + paracetamolopioidUmiarkowana

    Caution should be exercised when JUXTAPID is used with other medications known to have potential for hepatotoxicity, such as isotretinoin, amiodarone, acetaminophen (>4 g/day for ≥3 days/week), methotrexate, tetracyclines, and tamoxifen. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Tygecyklinaantybiotyk tetracyklinowyUmiarkowana

    Caution should be exercised when JUXTAPID is used with other medications known to have potential for hepatotoxicity, such as isotretinoin, amiodarone, acetaminophen (>4 g/day for ≥3 days/week), methotrexate, tetracyclines, and tamoxifen. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Warfarynalek przeciwzakrzepowyUmiarkowana

    Risk of Supratherapeutic or Subtherapeutic Anticoagulation with Warfarin JUXTAPID increases the plasma concentrations of warfarin. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Witamina EWitaminy i minerałyUmiarkowana

    In this trial, the median levels of serum vitamin E, ALA, linoleic acid, EPA, DHA, and arachidonic acid decreased from baseline to Week 26 but remained above the lower limit of the reference range. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Zasadowy cytrynian bizmutu + metronidazol + tetracyklinaantybiotykUmiarkowana

    Caution should be exercised when JUXTAPID is used with other medications known to have potential for hepatotoxicity, such as isotretinoin, amiodarone, acetaminophen (>4 g/day for ≥3 days/week), methotrexate, tetracyclines, and tamoxifen. (etykieta leku Lomitapid, Ostrzeżenia i środki ostrożności)

  • Zileutoninhibitor CYP1A2Umiarkowana

    …Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology (12.3) ] . (etykieta leku Lomitapid, Interakcje z innymi lekami)

Wzmianki o niewielkim znaczeniu (9)

  • Abrocytynibinhibitor JAKNiewielka

    P-glycoprotein Substrates Lomitapide is an inhibitor of P-glycoprotein (P-gp). (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Chinidynalek przeciwarytmicznyNiewielka

    P-glycoprotein Substrates Lomitapide is an inhibitor of P-glycoprotein (P-gp). (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Etrawirynalek przeciwretrowirusowyNiewielka

    P-glycoprotein Substrates Lomitapide is an inhibitor of P-glycoprotein (P-gp). (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Flibanserynalek działający depresyjnie na OUNNiewielka

    P-glycoprotein Substrates Lomitapide is an inhibitor of P-glycoprotein (P-gp). (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Ledipaswir + sofosbuwirlek przeciwwirusowyNiewielka

    P-glycoprotein Substrates Lomitapide is an inhibitor of P-glycoprotein (P-gp). (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Mitapiwatinduktor CYP3A4Niewielka

    P-glycoprotein Substrates Lomitapide is an inhibitor of P-glycoprotein (P-gp). (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Propafenonlek przeciwarytmicznyNiewielka

    P-glycoprotein Substrates Lomitapide is an inhibitor of P-glycoprotein (P-gp). (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Sofosbuwir + welpataswirlek przeciwwirusowyNiewielka

    P-glycoprotein Substrates Lomitapide is an inhibitor of P-glycoprotein (P-gp). (etykieta leku Lomitapid, Interakcje z innymi lekami)

  • Zonisamidlek przeciwdrgawkowyNiewielka

    P-glycoprotein Substrates Lomitapide is an inhibitor of P-glycoprotein (P-gp). (etykieta leku Lomitapid, Interakcje z innymi lekami)

Sprawdź, jak Lomitapid łączy się ze wszystkim, co przyjmujesz. Dodaj całą listę; wszystkie pary są sprawdzane jednocześnie.

Otwórz w wyszukiwarce

To nie jest porada medyczna. Stopień nasilenia odzwierciedla sformułowania etykiety, a nie indywidualne okoliczności. Oznaczenie „poważna” może dotyczyć połączenia stosowanego rutynowo pod nadzorem, a „niewielka” może mieć znaczenie przy dużych dawkach. Należy zapytać farmaceutę.